Portal de Periódicos da CAPES

Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada

2022; Oxford University Press; Volume: 75; Issue: 11 Linguagem: Inglês

10.1093/cid/ciac290

1537-6591

Danuta M. Skowronski, Yossi Febriani, Manale Ouakki, Solmaz Setayeshgar, Shiraz El Adam, Macy Zou, Denis Talbot, Natalie Prystajecky, John R. Tyson, Rodica Gilca, Nicholas Brousseau, Geneviève Deceuninck, Eleni Galanis, Christopher D. Fjell, Hind Sbihi, Élise Fortin, Sapha Barkati, Chantal Sauvageau, Monika Naus, David M. Patrick, Bonnie Henry, Linda Hoang, Philippe De Wals, Christophe Garenc, Alex Carignan, Mélanie Drolet, Agatha N. Jassem, Manish Sadarangani, Marc Brisson, Mel Krajden, Gaston De Serres,

Viral gastroenteritis research and epidemiology

The Canadian coronavirus disease 2019 (COVID-19) immunization strategy deferred second doses and allowed mixed schedules. We compared 2-dose vaccine effectiveness (VE) by vaccine type (mRNA and/or ChAdOx1), interval between doses, and time since second dose in 2 of Canada's larger provinces.